534 36. Sandri M, Sandri C, Gilbert A, Skuck C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117:399–412 37. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ (2004) The IGF-1/ PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14:395–403 38. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL (2004) IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol 287:E591–E601 39. Solomon V, Goldberg AL (1996) Importance of the ATP- ubiquitin-proteasome pathway in degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 271:26690–26697 40. Du J, Wang X, Meireles CL, Bailey JL, Debigare R, Zheng B, Price SR, Mitch WE (2004) Activation of caspase 3 is an initial step triggering muscle proteolysis in catabolic conditions. J Clin Invest 113:115–123 41. Wang XH, Hu Z, Hu JP, Du J, Mitch WE (2006) Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin- proteasome pathway by defects in muscle cell signaling. Endocrinology 147:4160–4168 42. Workeneh B, Rondon-Berrios H, Zhang L, Hu Z, Ayehu G, Ferrando A, Kopple JD, Wang H, Storer TW, Fournier M, Lee SW, Du J, Mitch WE (2006) Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. J Am Soc Nephrol 17:3233–3239 43. Mitch WE, Medina R, Greiber S, May RC, England BK, Price SR, Bailey JL, Goldberg AL (1994) Metabolic acidosis stimulates muscle protein degradation by activating the ATP-dependent pathway involving ubiquitin and proteasomes. J Clin Invest 93:2127–2133 44. DeFronzo RA, Beckles AD (1979) Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol 236:E328–E334 45. May RC, Bailey JL, Mitch WE, Masud T, England BK (1996) Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. Kidney Int 49:679–683 46. Hasselgren P-O, Warner BW, James H, Takehara H, Fischer JE (1987) Effect of insulin on amino acid uptake and protein turnover in skeletal muscle from septic rats: Evidence for insulin resistance of protein degradation. Arch Surg 122:228–233 47. Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA (2007) Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 71:146–152 48. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3:1014–1019 49. Bailey JL, Price SR, Zheng B, Hu Z, Mitch WE (2006) Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt path- way: implications for muscle atrophy. J Am Soc Nephrol 17:1388–1394 50. Saad MJ, Folli F, Kahn JA, Kahn CR (1993) Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidyli- nositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 92:2065–2072 51. May RC, Kelly RA, Mitch WE (1986) Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid- dependent mechanism. J Clin Invest 77:614–621 Pediatr Nephrol (2008) 23:527–535 52. Wing SS, Goldberg AL (1993) Glucocorticoids activate the ATP- ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol 264:E668–E676 53. Price SR, England BK, Bailey JL, Van Vreede K, Mitch WE (1994) Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle. Am J Physiol 267:C955–C960 54. Tiao G, Fagan J, Roegner V, Lieberman M, Wang J-J, Fischer JE, Hasselgren P-O (1996) Energy-ubiquitin-dependent muscle pro- teolysis during sepsis in rats is regulated by glucocorticoids. J Clin Invest 97:339–348 55. Mauras N (2001) Growth hormone therapy in the glucocorticosteroid- dependent child: metabolic and linear growth effects. Horm Res 56 (Suppl 1):13–18 56. Neu AM, Bedinger M, Fivush BA, Warady BA, Watkins SL, Friedman AL, Brem AS, Goldstein SL, Frankenfield DL (2005) Growth in adolescent hemodialysis patients: data from the Centers for Medicare & Medicaid Services ESRD Clinical Performance Measures Project. Pediatr Nephrol 20:1156–1160 57. Mehls O, Schaefer F, Tonshoff B, Wuhl E (2002) Effectiveness of growth hormone treatment in short children with chronic renal failure. J Pediatr 141:147–148 58. Fine RN, Sullivan EK, Tejani A (2000) The impact of recombinant human growth hormone treatment on final adult height. Pediatr Nephrol 14:679–681 59. Fischbach M, Terzic J, Menouer S, Dheu C, Soskin S, Helmstetter A, Burger MC (2006) Intensified and daily hemodialysis in children might improve statural growth. Pediatr Nephrol 21: 1746–1752 60. Cai D, Frantz JD, Tawa NE, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119:285–298 61. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183–190 62. Lee SJ (2004) Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20:61–86 63. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee S-J (2002) Induction of cachexia in mice by systemically administered myostatin. Science 296:1486–1488 64. McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma M, Kambadur R (2006) Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mech- anism. J Cell Physiol 209:501–514 65. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682–2688 66. Sun DF, Xheng Z, Tummala P, Oh J, Schaefer F, Rabkin R (2004) Chronic uremia attenuates growth hormone-induced signal trans- duction in skeletal muscle. J Am Soc Nephrol 15:2630–2636 67. Wang H, Casaburi R, Taylor WE, Aboellail H, Storer TW, Kopple JD (2005) Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I receptor is decreased in sedentary chronic hemodialysis patients. Kidney Int 68:352–361 68. Kalhoff H, Diekmann L, Kunz C, Stock GJ, Manz F (1997) Alkali therapy versus sodium chloride supplement in low birthweight infants with incipient late metabolic acidosis. Acta Paediatr 86:96–101 69. Boirie Y, Broyer M, Gagnadoux MF, Niaudet P, Bresson J-L (2000) Alterations of protein metabolism by metabolic acidosis in children with chronic renal failure. Kidney Int 58:236–241